Synergy Pharmaceuticals Inc. $200 Million Convertible Senior Notes Offering
Davis Polk acted as special product counsel for Merrill Lynch, Pierce, Fenner & Smith Incorporated as representative of the initial purchasers in connection with a Rule 144A offering by Synergy Pharmaceuticals Inc. of an aggregate principal amount of $200 million of 7.5% convertible senior notes due 2019, which included $25 million aggregate principal amount of convertible senior notes issued pursuant to the exercise in full of the initial purchasers’ over-allotment option.